(Adds details throughout)
Nov 22 (Reuters) - Lexicon Pharmaceuticals said on Friday it would reduce its workforce by about 60%, after the U.S. Food and Drug Administration noted deficiencies in its application seeking approval for its diabetes drug.
This comes days after a panel of advisers to the FDA voted against recommending the drug, sotagliflozin, as an add-on treatment to insulin therapy for managing blood glucose levels in adults with type 1 diabetes and chronic kidney disease.
Shares of the biopharma firm were down nearly 12% at 68 cents in premarket trading.
Lexicon said it will eliminate its commercial field team and stop promotional efforts for its approved heart failure treatment, Inpefa.
However, the company said it will continue to manufacture and make Inpefa available to patients and existing prescribers.
As part of the restructuring, Lexicon aims to reduce operating costs by $100 million in 2025.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shreya Biswas)
((Mariam.ESunny@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。